Semaglutide and menstrual changes

Women starting semaglutide sometimes report changes to their menstrual cycle, including heavier periods, irregular timing, or shifts in flow duration. The FDA-approved Wegovy label does not list menstrual irregularity as a clinical-trial adverse event in humans^[1], but a 2026 pharmacovigilance analysis of FDA adverse-event reports found a statistically significant association between semaglutide and menstrual abnormalities^[2]. The short answer: the signal is real, the mechanism is not fully understood, and anyone experiencing major changes should talk to their prescriber.

What the prescribing label says (and does not say)

The current Wegovy prescribing information on DailyMed notes one relevant nonclinical finding: "an increase in estrus cycle length was observed at all dose levels" in female rats, attributed to the pharmacological effects of semaglutide on food consumption^[1]. In the human clinical-trial data, menstrual irregularities are not listed among the adverse reactions. That does not mean they do not occur. Clinical trials track pre-specified endpoints and may not capture menstrual changes unless the study protocol measures them directly.

The label also requires that women discontinue Wegovy at least two months before a planned pregnancy due to the drug's long half-life^[1]. This washout recommendation reflects concern about fetal exposure, not menstrual effects, but it is a reminder that semaglutide's presence in the body persists well beyond the last injection.

What post-market safety data show

Lee and Kim (2026) analysed 759 reproductive and endocrine cases in the FDA Adverse Event Reporting System (FAERS) from mid-2022 through mid-2025. Semaglutide showed a positive statistical association with menstrual abnormalities and hormonal disturbances, while dulaglutide and tirzepatide showed inverse associations for heavy menstrual bleeding, dysmenorrhoea, and amenorrhoea^[2]. FAERS data are self-reported and cannot prove causation, but the pattern suggests that not all GLP-1 receptor agonists carry the same reproductive signal.

Weight loss, hormones, and cycle changes

Rapid weight loss from any cause can alter oestrogen levels, because adipose tissue produces oestrone (a form of oestrogen). Losing a significant amount of body fat can shift the hormonal balance that regulates the menstrual cycle. A 2023 meta-analysis of 11 randomised controlled trials (840 women with polycystic ovary syndrome) found that GLP-1 receptor agonists significantly improved menstrual regularity compared with controls^[3]. A separate study by Carmina and Longo found that 80% of obese PCOS patients who responded to semaglutide normalised their menstrual cycles after treatment^[4]. In these populations, the cycle change was a benefit, not a side effect.

For women without PCOS who had regular cycles before starting semaglutide, the picture is different. The same hormonal shifts driven by rapid fat loss can push a previously regular cycle into temporary irregularity, heavier flow, or spotting. This is not unique to semaglutide. It has been reported with bariatric surgery, very-low-calorie diets, and other interventions that produce fast weight reduction. The speed of fat loss matters: a slower titration schedule and gradual caloric deficit tend to produce fewer hormonal disruptions than aggressive early weight loss, though this has not been tested in a controlled trial specific to GLP-1 agonists and menstruation.

Oral contraceptives and semaglutide

GLP-1 receptor agonists slow gastric emptying, which raises a reasonable question about whether they reduce absorption of oral contraceptive pills. For semaglutide specifically, pharmacokinetic data in the prescribing label show no clinically relevant reduction in ethinylestradiol or levonorgestrel exposure^[1]. The Reproductive Health Access Project notes that semaglutide and liraglutide have no documented effect on oral contraceptive bioavailability, unlike tirzepatide, which can reduce contraceptive exposure by roughly 20% after a 5 mg dose^[5].

What we do not yet know

No large prospective study has been designed specifically to measure how semaglutide affects the menstrual cycle in women without PCOS. The FAERS signal points to a pattern worth investigating, but pharmacovigilance data cannot separate the drug's direct hormonal effects from the indirect effects of rapid weight loss. Whether the cycle changes are transient (resolving after weight stabilises) or persistent on continued treatment is also unanswered.

It is also unclear whether dose level matters. Wegovy's maintenance dose (2.4 mg weekly) is more than double the highest Ozempic dose (1 mg weekly), and higher doses produce faster weight loss. Whether menstrual disruption correlates with the pace of weight reduction, the absolute semaglutide dose, or both is an open question. Anyone experiencing heavy or prolonged bleeding, missed periods, or new cycle irregularity while on semaglutide should raise it with their prescriber. Menstrual changes can also signal conditions unrelated to medication.

For more on semaglutide's broader safety profile, including gastrointestinal side effects and the thyroid C-cell tumour boxed warning, see our semaglutide overview.